TICKERNERD
Menu
CORCORHealthcare · Medical Distribution

COR Stock Forecast: Cencora, Inc. Price Predictions for 2026-2027

Last close, 5 Nov 2026
$340
−4.05% on the day

The 14 Wall Street analysts covering Cencora, Inc. hold a median 12-month price target of $376 — +10.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 5 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$64.8B
Ticker Nerd rank
77/ 100
Median analyst target
$376
Analysts covering
14
Revenue$84.8B+5.1% y/y
Operating income$1.2B
Net income$776.7M
Free cash flow$2.4B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.8%
1M
+7.9%
YTD
+1.2%
1Y
−3.3%
From 52W high
−8.8%
From 52W low
+35.0%
$252
$373
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cencora, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Nov 2026
77/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
91
Growth
82
Quality
75
Momentum
72
Issuance
61
Revisions
59
Accruals
39
Size
4

Volatility (99): The share price has been relatively steady.

Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

COR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Jan 26Apr 26Jul 26Oct 26CORHigh $400Median $376Low $330

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
10 Buy4 Hold0 Sell
Low $330Median $376High $400

The green dot is the last close — the median target sits +10.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
30 Oct 2026Morgan StanleyMaintainsOverweight$346 → $377
22 Oct 2026BairdMaintainsOutperform—
22 Oct 2026BairdMaintainsOutperform$373 → $375
20 Oct 2026Argus ResearchMaintainsBuy—
20 Oct 2026Argus ResearchMaintainsBuy$340 → $380
16 Oct 2026UBSMaintainsBuy—
16 Oct 2026UBSMaintainsBuy$430 → $400
7 Oct 2026Leerink PartnersMaintainsOutperform$380 → $388
7 Oct 2026Leerink PartnersMaintainsOutperform—
8 Sept 2026RBC CapitalReiteratesSector Perform—
8 Sept 2026RBC CapitalReiteratesSector Perform$330
19 Aug 2026RBC CapitalInitiatesSector Perform$330
19 Aug 2026RBC CapitalInitiatesSector Perform—
11 Aug 2026Wells FargoMaintainsOverweight—
11 Aug 2026Wells FargoMaintainsOverweight$331 → $395
7 Aug 2026JP MorganMaintainsOverweight$382 → $390
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026Morgan StanleyMaintainsOverweight$342 → $346
7 Aug 2026Morgan StanleyMaintainsOverweight—
6 Aug 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

COR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

COR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Nov 2026, Cencora, Inc. returned −3.3% against +9.3% for the S&P 500, dividends included.

COR vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26CORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
10
Analysts cutting
0
Fundamentals

Cencora, Inc. (COR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.9×

Cheaper than 39% of US stocks

Price / sales
0.2×

Cheaper than 92% of US stocks

Price / book
17.6×

Cheaper than 5% of US stocks

EV / EBITDA
13.2×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
5.5%

Higher than 41% of US stocks

Earnings growth (YoY)
5.1%

Higher than 42% of US stocks

Gross margin
4.3%

Higher than 6% of US stocks

Operating margin
1.3%

Higher than 47% of US stocks

Net margin
1.0%

Higher than 49% of US stocks

Returns & dividend
Return on equity
129.0%

Higher than 97% of US stocks

Return on assets
3.5%

Higher than 68% of US stocks

Dividend yield
0.7%

Higher than 67% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cencora, Inc. (COR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cencora, Inc. has a market value of $64.8B and an enterprise value of $73.9B.

  • Revenue in the twelve months to 30 June 2026: $332.8B. The latest quarter grew 5.5% year on year.

  • Net income over the same four quarters: $2.6B, a 0.8% net margin.

  • Diluted earnings per share, trailing twelve months: $13.46.

  • Free cash flow in the twelve months to 30 June 2026: $4.1B, after $760.8M of capital spending.

  • Cencora, Inc. spent $1.0B on share buybacks and $468.1M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 190.8M.

  • Trailing P/E: 18.9×; forward P/E: 15.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.71%, paying out 17% of earnings.

  • Cencora, Inc. employs 47,000 people — $7.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Nov 2026

Data provided by Twelve Data

Peers

COR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
CORCencora, Inc.$64.8B77
CAHCardinal Health, Inc.$62.0B98
MCKMcKesson Corp.$125.5B93
HSICHenry Schein, Inc.$9.8B82
BSXBoston Scientific Corp.*$66.2B57
BDXBecton, Dickinson & Co.*$58.8B92
EWEdwards Lifesciences Corp.*$58.1B87

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cencora, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COR news & analysis

What Cencora (COR) Said on Its Q4 Earnings Call

MarketBeat · 5 Nov 2026positive

Cencora reported higher fiscal fourth-quarter revenue and adjusted earnings, with specialty drug sales and its OneOncology acquisition contributing to growth. It also introduced a reporting structure separating specialty operations from broader pharmaceutical distribution.

Why it matters — COR watchers may find the results and new reporting structure relevant to tracking the company’s business performance and operations.

Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand

Zacks Investment Research · 4 Nov 2026positive

Cencora reported fourth-quarter earnings and revenue above estimates, supported by specialty drug demand, with margins expanding. The company also raised its fiscal 2027 outlook.

Why it matters — The results and outlook update provide COR watchers with information on specialty-driven growth, margin trends, and the company’s expectations for fiscal 2027.

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript

Seeking Alpha · 4 Nov 2026neutral

The item is a transcript of Cencora, Inc.’s Q4 2026 earnings call; the excerpt provides no details about the discussion or results.

Why it matters — COR watchers may consult the transcript for management commentary, but the supplied excerpt contains no specifics to assess.

Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 4 Nov 2026neutral

Zacks notes that Cencora reported Q4 revenue and EPS for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago figures.

Why it matters — The comparisons provide COR watchers additional context for assessing the quarter’s results.

Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates

Zacks Investment Research · 4 Nov 2026positive

Cencora reported quarterly earnings of $4.66 per share, above the Zacks Consensus Estimate of $4.56. Earnings were $3.84 per share in the same period a year ago.

Why it matters — The earnings beat and year-over-year increase provide COR watchers with an update on the company’s quarterly results.

FAQ

Frequently asked questions about COR stock

What is the COR stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Cencora, Inc. have a median 12-month price target of $376, with estimates ranging from $330 to $400. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COR stock a buy right now?

Of the 14 analysts covering Cencora, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cencora, Inc. 77 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COR?

As at 5 Nov 2026, Cencora, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will COR stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +10.7% from the last close, and Ticker Nerd's factor model ranks Cencora, Inc. 77 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COR stock forecast for 2030?

No analyst covering Cencora, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $330 to $400 over the next 12 months.

How has COR stock performed over the past year?

Cencora, Inc. returned -3.3% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cencora, Inc. do?

Cencora Inc. is a global pharmaceutical solutions company focused on the sourcing, distribution, and commercialization of medicines and healthcare products.

What is the latest news on COR?

The most recent item we track (MarketBeat, 5 Nov 2026): "What Cencora (COR) Said on Its Q4 Earnings Call". Cencora reported higher fiscal fourth-quarter revenue and adjusted earnings, with specialty drug sales and its OneOncology acquisition contributing to growth. It also introduced a reporting structure separating specialty operations from broader pharmaceutical distribution.

Company

About Cencora, Inc.

Cencora Inc. is a global pharmaceutical solutions company focused on the sourcing, distribution, and commercialization of medicines and healthcare products. The company supports manufacturers, pharmacies, hospitals, health systems, and other care providers through wholesale distribution, specialty pharmacy services, patient access support, and supply chain solutions. Its business also includes international pharmaceutical wholesale, global commercialization services, and logistics for temperature-sensitive therapies. Cencora serves both human and animal health markets, helping improve product availability and operational efficiency across the healthcare ecosystem. Headquartered in Conshohocken, Pennsylvania, Cencora operates as a key intermediary in the pharmaceutical supply chain, connecting drug makers with the organizations that deliver care.

CEO Dr. Robert P. Mauch Ph.D., PharmD · 47,000 employees · United States · https://www.cencora.com